INTRODUCTION
============

Regulated upon activation normal T-cell expressed and secreted (RANTES) is a key signaling cytokine involved in initiation of physiologic inflammation ([@R7]) as well as in many pathologic inflammatory conditions including endometriosis ([@R19]). RANTES has been shown to be responsible for 70% of the stimulation of monocyte migration caused by peritoneal fluid from women with endometriosis ([@R9]). Some authors have suggested that RANTES production might be inhibited by activation of the PPAR pathway. Thiazolidinediones including rosiglitazone and pioglitazone are a new class of insulin sensitizers that do not stimulate insulin secretion ([@R1]). These drugs act as PPAR-*γ* agonists, alter gene expression, enhance the sensitivity of tissue to insulin, and partially reverse lipid abnormalities in patients with diabetes ([@R17]). Therefore, theses drugs have been used for patients with polycystic ovary syndrome (PCOS) undergoing IVF treatment. Our previous study demonstrated that pioglitazone therapy reduces intraovarian stromal blood flow and is beneficial in improving both the response to ovarian stimulation and IVF outcome in PCOS patients undergoing IVF ([@R12]). It has been reported that PPAR-*γ* also has a beneficial effect on endometriosis. In an *in vitro* study, PPAR-*γ* reduced the monocyte migration induced by peritoneal fluid from women with endometriosis ([@R10]). Therefore, we performed this study to investigate the effect of pioglitazone, a drug of the thiazolidinedione class, on production of RANTES and *in vitro* fertilization-embryo transfer (IVF-ET) outcomes in infertile patients with stage II or IV endometriosis undergoing IVF treatment.

MATERIAL AND METHODS
====================

1.. Patients
------------

Sixty-four infertile patients with stage III or IV endometriosis who underwent IVF were prospectively recruited to this randomized study, which was performed at the university-based infertility clinic of the Asan Medical Center, Seoul, South Korea. All subjects were diagnosed by laparoscopic surgery and histologic examination with stage III or IV endometriosis according to the revised American Society for Reproductive Medicine (ASRM) classification. All patients provided written informed consent. Patients were randomly allocated to the treatment group (n=32) or the placebo group (n=32) by number allocation using sealed envelopes. A power calculation showed 82% when each groups consisted of 32 patients. All patients had endometriosis, and had failed to ovulate or conceive after repeated treatment with clomiphene citrate or gonadotropin. All patients were in good health with normal thyroid, hepatic, and renal function. Blood samples were collected from each patient on menstrual cycle day (MCD) 3 for basal measurement of sex hormone and prolactin levels.

2.. Controlled Ovarian Stimulation (COS)
----------------------------------------

The long protocol of GnRH agonist (GnRH-a) was used for COS in all patients. Daily injection of a GnRH agonist 1 mg (Leuprorelin acetate, Lorelin; Dongkook, Korea) was initiated commencing at the midluteal phase and was continued until menses, followed by a dose reduction to 0.5 mg daily. Ovarian stimulation was started with 50--150 IU of recombinant human follicle-stimulating hormone (rhFSH, Puregon; Organon, Oss, the Netherlands) on menstrual day 3. The initial dose of rhFSH was calculated with reference to patient age and body mass index. When one or more follicles attained a mean diameter of ≥ 18 mm, 250 *μ*g hCG was subcutaneously administered to induce follicular maturation.

In the pioglitazone treatment group, pioglitazone (Actos; Takeda, Osaka, Japan), 15 mg once daily, was given on the commencement day of GnRH-a administration to the day of human chorionic gonadotropin (hCG, Ovidrel; Serono, Geneva, Switzerland) injection. In the control group, placebo was administered during the same period. Oocytes were retrieved 35--36 hours later, and one to four embryos were transferred to the uterus three days later. During the luteal phase, 90 mg of vaginal progesterone gel (Crinone 8%; Serono) was applied once daily, starting on the day of oocyte retrieval. Pregnancies were identified by an increase in serum *β*-hCG concentration and transvaginal ultrasonographic evidence of a gestational sac. Serum concentrations of *β*-hCG were measured 11 days after embryo transfer (ET) by radioimmunoassay using an hCG MAIA clone kit (Serono Diagnostics, Woking, UK); the inter- and intra-assay variances values were \<10% and 5%, respectively. A clinical pregnancy was defined as the presence of a gestational sac on ultrasonography. Blood samples were drawn for serologic assay of RANTES on the day on which the GnRH agonist was first administered and the day of HCG injection. We analyzed serum RANTES concentrations before and after treatment in both groups. RANTES was measured using a solid-phase enzyme-linked immunosorbent assay (Medgenix Diagnostics, Fleurus, Belgium); interassay and intraassay variances were less than 10% and 5%, respectively.

3.. Statistical analysis
------------------------

Results are reported as means ± standard deviations (SDs). The Chi-squared test, Fisher's exact test, the Mann-Whitney *U* test and Spearman's coefficient of correlation were used, as appropriate, in comparisons. Statistical significance was defined as *P*\<0.05. The SPSS statistical package for Windows, version 11.0 (SPSS Inc, Chicago, IL) was used for all analyses.

RESULTS
=======

Patients' clinical characteristics and baseline hormone concentrations were similar in the pioglitazone and control groups (Table [1](#T1){ref-type="table"}). Table [2](#T2){ref-type="table"} shows the COS results and IVF-ET outcomes. There were no differences between the two groups in the total dose of rhFSH administered, and the numbers of oocytes retrieved, oocytes fertilized and grade I or II embryos. The clinical pregnancy rate was somewhat higher in the pioglitazone group of 37.5% compared with 31.3% of the control group, but the difference did not achieve the statistical significance. However, the embryo implantation rate was significantly higher in the pioglitazone group than in the control group (13.8% vs. 8.6%, *P*\<0.01). There was no significant difference between the two groups in the miscarriage rates.

###### 

Patient characteristics

  --
  --

###### 

Comparison of controlled ovarian stimulation results and IVF-ET outcome

  --
  --

When COS results and IVF outcomes were compared between pregnant and non-pregnant subgroups of the pioglitazone group, there were no significant differences between pregnant and non-pregnant subgroups in the numbers of oocytes retrieved, mature oocytes, oocytes fertilized and embryos transferred.

The serum RANTES concentrations of the pioglitazone and control groups are shown in Fig. [1](#F1){ref-type="fig"}. RANTES concentrations after pioglitazone treatment decreased significantly compared with that before pioglitazone treatment (*P*\<0.01). However, RANTES concentration before and after placebo treatment was not different in the control group. In the pregnant subgroup of the pioglitazone group, RANTES concentration before pioglitazone treatment was significantly lower than in the non-pregnant subgroup (*P*\<0.05). After pioglitazone treatment, RANTES concentrations decreased significantly in both subgroups (*P*\<0.01 in the pregnant subgroup, *P*\<0.05 in the non-pregnant subgroup).

![**Plasma RANTES levels in patients with endometriosis who underwent IVF-ET before and after pioglitazone treatment**.](devrepro-17-207-g001){#F1}

DISCUSSION
==========

Endometriosis is an inflammatory disease characterized by the presence of endometrial glandular and stromal cells in areas outside of the uterine corpus. The reported disease prevalence varies widely depending on the population studied and the method of sampling employed, the prevalence of endometriosis appears to range from 2% to 18%, whereas within infertile populations the prevalence has been reported to be as high as 50% ([@R18]). Endometriosis is associated with activation of immune cells and aberrant cytokine production in peritoneal fluid, creating a local inflammatory environment ([@R16]; [@R23]).

In pathologic states including chronic endometritis and endometriosis, inflammation followed by cellular infiltration into the area of interest and is followed by differentiation and activation of immune cells ([@R20]). Such cells secrete growth factors, cytokines, prostanoids, complement components, and hydrolytic enzymes ([@R19]). These signals are released into the blood-stream and chemoattract other immune cells. The levels of cytokines associated with inflammation have been reported to be higher in women with endometriosis ([@R6]) as well as in those with unexplained infertility ([@R8]). Both ectopic and eutopic endometrium can be stimulated to produce materials chemoattracting mononuclear cells, including monocyte chemotactic protein-1 (MCP-1) ([@R4]), interleukin-8 (IL-8) ([@R3]) and RANTES ([@R11]). Many studies have demonstrated abnormal local endometrial production of pro-inflammatory cytokines, such as tumor necrosis factor a (TNF-a), IL-1, IL-6, and IL-8 ([@R13]). Increasing evidence indicates that RANTES is the key chemokine involved at early stages of the inflammatory process ([@R2]). One report showed that RANTES is responsible for 70% of the *in vitro* monocyte migration activity in peritoneal fluid from women with endometriosis ([@R9]). Subsequent activation of cellular inflammatory mediators might be prevented by blocking of early monocyte infiltration.

PPAR plays a key role in the regulation of inflammation and insulin secretion ([@R24]). Komar et al. ([@R14]) demonstrated transcription of PPAR-*γ* in rat granulosa cells. As well as exerting multiple effects on insulin production, recently thiazolinediones have been shown to exhibit both insulin-independent and insulin-sensitizing direct effects on steroidogenesis and production of IGF binding protein-1 in human ovarian cells. This implies that PPAR-*γ* is expressed in the human ovary ([@R21]). It has been reported that PPAR-*γ* also affect RANTES secretion even in the endometrial stromal cells ([@R20]). The cited *in vitro* study suggested that PPAR inhibits the pathway leading to RANTES expression in endometrial stromal cells. By binding to rosiglitazone, PPAR-*γ* receptor-ligand complexes seem to interact with response elements on the RANTES gene promoter, thereby blocking the subsequent transcription and translation of RANTES ([@R20]). However, studies on the effect of PPAR-*γ* or PPAR-*γ* agonist on RANTES secretion in endometriosis or endometrial tissue are very limited. Moreover, it is hard to find out the study on the effect of PPAR-*γ* agonist on RANTES and IVF outcome in patients with endometriosis.

Our study is the first report on the effect of thiazolinediones on RANTES secretion and IVF outcome in infertile women with advanced endometriosis undergoing IVF treatment. In the present study, we used a pioglitazone as a PPAR-*γ* ligand to treat infertile patients with endometriosis and evaluated whether PPAR-*γ* ligand such as pioglitazone could inhibit production of RANTES via activation of the PPAR pathway and improve IVF outcomes in infertile patients with advanced endometriosis undergoing IVF. As we expected before study, pioglitazone had a beneficial effect on RANTES secretion and IVF outcome in advanced enometriosis patients.

The thiazolidinediones including rosiglitazone and pioglitazone belong to a new class of insulin sensitizers that do not stimulate insulin secretion. The first available drug of the thiazolidinedione class, troglitazone, was effective to induce ovulation in patients with polycystic ovary syndrome (PCOS), but was later reported to be associated with fatal hepatotoxicity ([@R5]). This caused the U.S. Food and Drug Administration (FDA) to withdraw approval of the drug. Rosiglitazone, another thiazolidinedione, has also been shown to be effective in inducing ovulation in PCOS patients. Few side-effects are evident in healthy subjects. However, the FDA encourages healthcare professionals to follow current recommendations on the drug label, including a contraindication of rosiglitazone use in patients with NYHA Class III or IV heart failure, and avoidance of use in patients with symptomatic heart failure. All patients should be monitored for signs and symptoms of heart failure (rapid weight gain, difficulty in breathing, and/or swelling) after initiation of treatment and after an increase in dose ([@R15]; [@R22]).

We have shown that administration of pioglitazone reduced the serum concentration of RANTES. Although the response to ovarian stimulation did not improve, the implantation rate was significantly higher in the treatment group. Further, in the pregnant subgroup, RANTES concentration was significantly lower than in the non-pregnant subgroup. Statistically significant differences in RANTES concentrations were evident before and after treatment. However, However, our study has a limitation to evaluate the efficacy of pioglitazone treatment in endometriosis patients due to a small number of sample available. Therefore, well-designed larger studies with longer follow-up times are needed to confirm the effectiveness and safety of pioglitazone.
